Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug allergy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Drug allergy. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-017828-54 Sponsor Protocol Number: 1131/09 Start Date*: 2011-03-28
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to -lactams.
    Medical condition: allergy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013661 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003856-22 Sponsor Protocol Number: C-07-01 Start Date*: 2017-11-07
    Sponsor Name:Alcon Research Ltd
    Full Title: Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray in 6-11 Year old Patients.
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039776 Seasonal allergic rhinitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001318-14 Sponsor Protocol Number: PHT-01-13 Start Date*: 2013-07-15
    Sponsor Name:PH&T SpA
    Full Title: MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF SEASO...
    Medical condition: SEASONAL ALLERGIC RHINITIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000754-19 Sponsor Protocol Number: AL1602av Start Date*: 2017-11-09
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002409-13 Sponsor Protocol Number: AL1501AV Start Date*: 2015-11-19
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparati...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10039776 Seasonal allergic rhinitis LLT
    19.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    19.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    19.0 100000004855 10001705 Allergic asthma LLT
    19.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001538-18 Sponsor Protocol Number: 603-PG-PSC-74 Start Date*: 2004-09-23
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomised, double blinded, placebo controlled multicentre study for the efficacy and safety of Depigoid birch pollen
    Medical condition: Patients have to suffer from IgE mediated allergic rhinits, rhinoconjunctivitis +/- asthma due to sensitization again birch pollen.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10036019 LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005400-28 Sponsor Protocol Number: AL1502AV Start Date*: 2016-06-20
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhin...
    Medical condition: Patients with seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma during the birch pollen season
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013269-24 Sponsor Protocol Number: 1268.41 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, double-blind, triple dummy, partial cross-over (each active treatment with placebo) study using an Environmental Challenge Chamber (ECC) to assess the safety and efficacy of 2 weeks of ...
    Medical condition: Allergic rhinitis due to pollen
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002296-42 Sponsor Protocol Number: SC-21A Start Date*: 2020-01-31
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002319-27 Sponsor Protocol Number: SL-61A Start Date*: 2021-02-01
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy
    Medical condition: Birch pollen-related allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.1 100000004870 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000097-38 Sponsor Protocol Number: LLB-2016-01 Start Date*: 2016-02-17
    Sponsor Name:Labo'Life
    Full Title: Randomized, double-blind, placebo-controlled study to measure 2L®ALERG (homeopathic drug) efficacy on symptoms of allergic rhinitis and allergic rhinoconjunctivitis in patients with a seasonal alle...
    Medical condition: Patients: Allergic Rhinitis and allergic rhinoconjunctivitis in patients with seasonal allergy to grass pollen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004094-52 Sponsor Protocol Number: R5713-5714-5715-ALG-2001 Start Date*: 2021-02-19
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
    Medical condition: Birch Pollen Allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002881-42 Sponsor Protocol Number: SL-351A Start Date*: 2023-02-07
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhino-conjunctivitis (with well-controlled mild-to-moderate or without asthma)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004185-14 Sponsor Protocol Number: CDPG103ADE01 Start Date*: 2012-02-29
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldeh...
    Medical condition: Allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039776 Seasonal allergic rhinitis LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000442-35 Sponsor Protocol Number: CS-BM32-003 Start Date*: 2012-05-10
    Sponsor Name:Biomay AG
    Full Title: PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY
    Medical condition: Grass pollen allergy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000548-25 Sponsor Protocol Number: AL1605av Start Date*: 2018-06-18
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid...
    Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10001705 Allergic asthma LLT
    21.1 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004050-31 Sponsor Protocol Number: SAN-0677 Start Date*: 2022-04-04
    Sponsor Name:Lek Pharmaceuticals d.d.
    Full Title: A multicenter, randomized, double-blind, placebo and active controlled parallel-group trial to assess the efficacy and safety of the fixed combination medicinal product Mometasone furoate + Azelast...
    Medical condition: Seasonal allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005939-15 Sponsor Protocol Number: DC04/RUP/3/08 Start Date*: 2009-02-11
    Sponsor Name:J. Uriach y Compañía, S.A.
    Full Title: Efficacy and safety of rupatadine in persistent allergic rhinitis and health-related quality of life in children age 6-11 years: A randomized, double blind, placebo-controlled clinical trial.
    Medical condition: Persistent Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034382 Perennial allergic rhinitis LLT
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002259-32 Sponsor Protocol Number: AN004T Start Date*: 2012-08-14
    Sponsor Name:Anergis SA
    Full Title: A multicentre, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT, a combination of contiguous overlapping peptides derived ...
    Medical condition: Desensitization by Specific ImmunoTherapy (SIT) in subjects allergic to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10066093 Birch pollen allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) DK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-001227-12 Sponsor Protocol Number: M19-850 Start Date*: 2020-03-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3b, open label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study
    Medical condition: Moderate to severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) HU (Completed) CZ (Completed) ES (Ongoing) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HR (Completed) IT (Completed) NO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 17:09:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA